Business context and reporting period
NanoViricides, Inc. filed this unaudited Form 10-Q for the three months ended September 30, 2017, its fiscal first quarter. The pre-revenue biotechnology company develops antiviral drug candidates and reported that all programs remained in preclinical or advanced preclinical development. Work was primarily focused on HerpeCide candidates, particularly a topical shingles treatment; FluCide and other programs received lower priority.
Financial performance and position
| Metric | Quarter ended Sep. 30, 2017 | Prior-year quarter / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.16 million | $1.45 million; down $297,000 |
| General and administrative expense | $1.08 million | $988,000; up $87,000 |
| Total operating expenses | $2.23 million | $2.44 million |
| Net loss | $2.01 million; $0.03 per share | $3.06 million; $0.05 per share |
| Cash used in operations | $1.56 million | $2.22 million |
| Cash and cash equivalents | $13.51 million at Sep. 30 | $15.10 million at Jun. 30 |
| Total liabilities | $6.75 million | $6.68 million at Jun. 30 |
Operating expenses exceeded revenue, so operating and profit margins are not meaningful. Net loss improved year over year, reflecting lower R&D expense and a $565,000 noncash gain from changes in derivative fair value; this gain is not operating cash generation. Interest expense was $125,000, while convertible-debenture discount amortization was $239,000. The balance sheet showed $18.52 million in stockholders’ equity and a $77.13 million accumulated deficit.
Current liabilities were $5.28 million, including $4.20 million of Series C debentures net of discount, $819,000 payable to related party TheraCour, and $125,000 of deferred interest payable. The $5 million Series C debenture was due June 30, 2018. The company reported no other long-term debt, apart from convertible debentures, and no off-balance-sheet arrangements.
Material changes versus the prior comparable period
- R&D spending declined 20% year over year, primarily due to lower payroll, lab supplies and materials, and no new third-party laboratory agreements or laboratory fees in the quarter.
- G&A expense increased about 9%, primarily due to higher general operating expenses.
- Net loss narrowed by about $1.06 million. Lower operating costs and the derivative fair-value gain contributed; the latter is noncash and valuation-dependent.
- Cash declined $1.59 million from June 30, 2017. Accounts payable to TheraCour rose from $341,000 to $819,000.
Outlook, commentary, risks and unusual items
Management said existing cash should fund operations at the current spending rate through November 2018, but was insufficient for the planned work beyond normal preclinical development toward an IND filing through that period. The company was seeking additional financing and said it could adjust development priorities if funds were unavailable. It gave no revenue or profitability guidance and cautioned that development timelines and costs could exceed estimates.
Management described the shingles candidate as nearing selection for preliminary rat toxicology work, with successful results expected to inform further safety and toxicology studies toward an IND. The filing also discussed reported preclinical findings for shingles and acute retinal necrosis; these are early-stage results and do not establish clinical efficacy or regulatory approval. Progress depends on further studies, funding, external collaborators and CROs, staffing, and regulatory work. The company noted that its Shelton facility was not yet fully prepared for cGMP production and that limited financing constrained hiring and quality-assurance and quality-control capabilities.
Key risks include continued losses and no foreseeable revenue, financing and dilution risk, uncertain drug-development outcomes and costs, reliance on third parties, and dependence on TheraCour licenses and services. The company reported no pending or threatened legal proceedings to its knowledge. Disclosure controls were assessed as effective at a reasonable-assurance level, with no material quarterly changes to internal control over financial reporting.
Subsequent event: On November 13, 2017, the company agreed with a director-controlled holder to redeem the $5 million Series C debenture by issuing 5.5 million common shares, including 500,000 shares for interest through the original maturity date, plus 150,000 Series A preferred shares in exchange for waiving early-redemption payments. The company estimated this would preserve about $5.5 million of cash otherwise payable to the holder. This transaction occurred after quarter-end and was not reflected in September 30 balances.
Important facts for investors to verify
- Confirm the post-quarter Series C redemption’s final share issuance, accounting treatment, and effect on fully diluted ownership and cash obligations.
- Assess whether cash and any new financing can fund both baseline operations and the planned IND-enabling work; management’s runway estimate applies to spending at the current rate.
- Track the shingles candidate selection, repeatability of preclinical results, toxicology and CMC milestones, and any actual IND submission or clinical-trial authorization.
- Review dependence on TheraCour, including the $819,000 related-party payable, development charges, license scope, and the still-pending licensing of certain herpesvirus indications.
- Reconcile the filing’s prepaid-expense figures: the balance sheet reports $192,420 at September 30, while MD&A cites $192,240.
- Consider dilution from warrants, preferred stock, service-related equity awards, and the debenture redemption; the filing excluded anti-dilutive securities from diluted loss per share.